Use of this platform facilitated the robust assessment of the intensity of in situ PD-1 and PD-L1 expression on different cell types within the melanoma TME, with 41 combinations of expression patterns identified using six markers (PD-1, PD-L1, CD8, FoxP3, CD163, and Sox10/S100). Here, CD163 is linked to melanoma.